The combination therapy of HDAC1 and aPKC inhibitors has been shown to prevent GLI1 nuclear maturation and effectively antagonize basal cell carcinoma (BCC) at lower doses than either agent alone. Here, HDAC1 is linked to skin basal cell carcinoma.